Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA~1. Age greater than or equal to 18 years at the time of signing of the ICF.~2. The patient agrees to comply with the contraception and reproduction restrictions of the study~3. Receiving intravenous (IV) or subcutaneous (SC) erythropoietin stimulating agents (ESA) drugs continuously prescribed for a minimum of 8 weeks prior to Screening~4. At least 2 ferritin values during Screening \> 300 ng/mL~5. At least 2 transferrin saturation (TSAT) values during Screening between 15% and 50% (inclusive)~EXCLUSION CRITERIA:~1. Use of systemic immunosuppressive drugs during the Screening Period or anticipated use of such drugs any time during the study~2. Clinical evidence or suspicion of active or smoldering infection by clinical or serologic criteria~3. Actively treated or active malignancy~4. Known or suspected occult or active bleeding~5. Received a red blood cell or whole blood transfusion within 2 months prior to Screening or anticipated to receive a blood transfusion at any time during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- COR-001 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).